Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2024

Open Access 01-12-2024 | Arterial Occlusive Disease | Research

Relationships of serum FGF23 and α-klotho with atherosclerosis in patients with type 2 diabetes mellitus

Authors: Jiao Bi, Mei Zheng, Ke Li, Siwei Sun, Zihang Zhang, Nana Yan, Xueping Li

Published in: Cardiovascular Diabetology | Issue 1/2024

Login to get access

Abstract

Background

Compelling evidence suggests that calcium/phosphorus homeostasis-related parameters may be linked to diabetes mellitus and cardiovascular events. However, few studies have investigated the association of fibroblast growth factor 23 (FGF23), α-klotho and FGF23/α-klotho ratio with atherosclerosis in patients with type 2 diabetes mellitus (T2DM).

Objective

This study was designed to evaluate whether FGF23, α-klotho and FGF23/α-klotho ratio are associated with T2DM and further to explore the relationships between these three factors and atherosclerosis in Chinese patients with T2DM.

Methods

Serum FGF23 and α-klotho levels were measured via an enzyme-linked immunosorbent assay (ELISA) kit, and the carotid intima-media thickness (CIMT) was assessed via high-resolution color Doppler ultrasonography. The associations of serum FGF23, α-klotho and FGF23/α-klotho ratio with atherosclerosis in T2DM patients were evaluated using multivariable logistic regression models.

Results

This cross-sectional study involved 403 subjects (207 with T2DM and 196 without T2DM), 41.7% of the patients had atherosclerosis, and 67.2% of the carotid intima were thickened to a thickness greater than 0.9 mm. Compared with those in the lowest tertile, higher tertiles of FGF23 levels and FGF23/α-klotho ratio were positively associated with T2DM after adjusting for covariates, and serum α-klotho concentration was inversely correlated with T2DM (all P values < 0.01). Moreover, elevated serum FGF23 levels and FGF23/α-klotho ratio were positively associated with CIMT and carotid atherosclerosis in T2DM patients (all P values < 0.01). Further spline analysis similarly revealed linear dose‒response relationship (all P values < 0.01). And there was still significant differences in CIMT and carotid atherosclerosis between the highest group of α-klotho and the reference group in T2DM patients (P values = 0.05).

Conclusions

T2DM was positively linearly related to serum FGF23 concentration and FGF23/α-klotho ratio, and negatively correlated with serum α-klotho concentration. Furthermore, both FGF23 and FGF23/α-klotho ratio were positively correlated with CIMT and atherosclerosis in T2DM patients, while α-klotho was inversely correlated with both CIMT and atherosclerosis, although the associations were not completely significant. Prospective exploration and potential mechanisms underlying these associations remain to be further elucidated.
Appendix
Available only for authorised users
Literature
1.
Davies MJ, et al. Management of hyperglycemia in type 2 diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753–86.PubMedPubMedCentralCrossRef
2.
Zhao D, et al. Epidemiology of cardiovascular disease in China: current features and implications. Nat Rev Cardiol. 2019;16(4):203–12.PubMedCrossRef
3.
Tall AR, Bornfeldt KE. Inflammasomes and atherosclerosis: a mixed picture. Circ Res. 2023;132(11):1505–20.PubMedCrossRef
4.
Wong ND, Sattar N. Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention. Nat Rev Cardiol. 2023;20(10):685–95.PubMedCrossRef
5.
6.
Heller SR. Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinol. 2019;7(5):385–96.CrossRef
7.
8.
Shimada T, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004;113(4):561–8.PubMedPubMedCentralCrossRef
9.
Stubbs JR, et al. Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol. 2007;18(7):2116–24.PubMedCrossRef
10.
11.
12.
Anour R, et al. Klotho lacks a vitamin D independent physiological role in glucose homeostasis, bone turnover, and steady-state PTH secretion in vivo. PLoS ONE. 2012;7(2):e31376.PubMedPubMedCentralCrossRef
13.
14.
Verkaik M, et al. FGF23 impairs peripheral microvascular function in renal failure. Am J Physiol Heart Circ Physiol. 2018;315(5):H1414–24.PubMedCrossRef
15.
Chen YX, et al. Klotho/FGF23 axis mediates high phosphate-induced vascular calcification in vascular smooth muscle cells via Wnt7b/β-catenin pathway. Kaohsiung J Med Sci. 2019;35(7):393–400.PubMedCrossRef
16.
Mirza MA, et al. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis. 2009;205(2):385–90.PubMedCrossRef
17.
Nagai R, et al. Endothelial dysfunction in the klotho mouse and downregulation of klotho gene expression in various animal models of vascular and metabolic diseases. Cell Mol Life Sci. 2000;57(5):738–46.PubMedCrossRef
18.
19.
Biscetti F, et al. Increased FGF23 serum level is associated with unstable carotid plaque in type 2 diabetic subjects with internal carotid stenosis. Cardiovasc Diabetol. 2015;14:139.PubMedPubMedCentralCrossRef
20.
Freedman BI, et al. Plasma FGF23 and calcified atherosclerotic plaque in African americans with type 2 diabetes Mellitus. Am J Nephrol. 2015;42(6):391–401.PubMedCrossRef
21.
Donate-Correa J, et al. Klotho as a biomarker of subclinical atherosclerosis in patients with moderate to severe chronic kidney disease. Sci Rep. 2021;11(1):15877.PubMedPubMedCentralCrossRef
22.
Willeit P, et al. Carotid intima-media thickness progression as surrogate marker for Cardiovascular Risk: Meta-Analysis of 119 clinical trials involving 100 667 patients. Circulation. 2020;142(7):621–42.PubMedPubMedCentralCrossRef
23.
Keles N, et al. Low serum level of Klotho is an early predictor of atherosclerosis. Tohoku J Exp Med. 2015;237(1):17–23.PubMedCrossRef
24.
Donate-Correa J, et al. Klotho inversely relates with carotid intima- media thickness in atherosclerotic patients with normal renal function (eGFR ≥ 60 mL/min/1.73m(2)): a proof-of-concept study. Front Endocrinol (Lausanne). 2023;14:1146012.PubMedCrossRef
25.
Gungor O, et al. The relationships between serum sTWEAK, FGF-23 levels, and carotid atherosclerosis in renal transplant patients. Ren Fail. 2013;35(1):77–81.PubMedCrossRef
26.
Donovan K, et al. Fibroblast growth Factor-23 and risk of Cardiovascular diseases: a mendelian randomization study. Clin J Am Soc Nephrol. 2023;18(1):17–27.PubMedCrossRef
27.
Takashi Y, et al. Circulating FGF23 is not associated with cardiac dysfunction, atherosclerosis, infection or inflammation in hemodialysis patients. J Bone Min Metab. 2020;38(1):70–7.CrossRef
28.
Castelblanco E, et al. Association of α-klotho with subclinical carotid atherosclerosis in subjects with type 1 diabetes mellitus. Cardiovasc Diabetol. 2022;21(1):207.PubMedPubMedCentralCrossRef
29.
30.
31.
Hanks LJ, et al. Associations of fibroblast growth factor-23 with markers of inflammation, insulin resistance and obesity in adults. PLoS ONE. 2015;10(3):e0122885.PubMedPubMedCentralCrossRef
32.
Marchelek-Mysliwiec M, et al. Association of FGF19, FGF21 and FGF23 with carbohydrate metabolism parameters and insulin resistance in patients with chronic kidney disease. J Appl Biomed. 2020;18(2–3):61–9.PubMedCrossRef
33.
Kutluturk Y, et al. The relationship between serum FGF-23 concentration and insulin resistance, prediabetes and dyslipidemia in obese children and adolescents. J Pediatr Endocrinol Metab. 2019;32(7):707–14.PubMedCrossRef
34.
Zubkiewicz-Kucharska A, Wikiera B, Noczyńska A. Soluble Klotho is decreased in children with type 1 diabetes and correlated with metabolic control. Front Endocrinol (Lausanne). 2021;12:709564.PubMedCrossRef
35.
Nie F, et al. Serum klotho protein levels and their correlations with the progression of type 2 diabetes mellitus. J Diabetes Complications. 2017;31(3):594–8.PubMedCrossRef
36.
Wang K, et al. Association between serum klotho levels and the prevalence of diabetes among adults in the United States. Front Endocrinol (Lausanne). 2022;13:1005553.PubMedCrossRef
37.
Bi X, et al. The protective role of Klotho in CKD-Associated Cardiovascular Disease. Kidney Dis (Basel). 2020;6(6):395–406.PubMedCrossRef
38.
Pasaoglu OT, et al. FGF23, alpha-klotho and vitamin D mediated calcium-phosphate metabolism in haemodialysis patients. J Med Biochem. 2021;40(2):160–6.PubMedPubMedCentralCrossRef
39.
Donate-Correa J et al. Pathophysiological implications of imbalances in fibroblast growth factor 23 in the development of diabetes. J Clin Med, 2021. 10(12).
40.
Lin Y, Sun Z. In vivo pancreatic β-cell-specific expression of antiaging gene Klotho: a novel approach for preserving β-cells in type 2 diabetes. Diabetes. 2015;64(4):1444–58.PubMedCrossRef
41.
Kurpas A et al. Fibroblast growth factor 23: potential marker of Invisible Heart damage in Diabetic Population. Biomedicines, 2023. 11(6).
42.
Marthi A, et al. Fibroblast growth Factor-23 and risks of Cardiovascular and Noncardiovascular diseases: a Meta-analysis. J Am Soc Nephrol. 2018;29(7):2015–27.PubMedPubMedCentralCrossRef
43.
Wojcik M, et al. The association of FGF23 levels in obese adolescents with insulin sensitivity. J Pediatr Endocrinol Metab. 2012;25(7–8):687–90.PubMed
44.
Garland JS, et al. Insulin resistance is associated with fibroblast growth Factor-23 in stage 3–5 chronic kidney disease patients. J Diabetes Complications. 2014;28(1):61–5.PubMedCrossRef
45.
Krick S, et al. FGF23 induction of O-Linked N-Acetylglucosamine regulates IL-6 secretion in human bronchial epithelial cells. Front Endocrinol (Lausanne). 2018;9:708.PubMedCrossRef
46.
Bułdak Ł. Cardiovascular Diseases-A focus on atherosclerosis, its Prophylaxis, complications and recent advancements in therapies. Int J Mol Sci, 2022. 23(9).
47.
Tuzun D, et al. Is FGF-23 an early indicator of atherosclerosis and cardiac dysfunction in patients with gestational diabetes? Arch Endocrinol Metab. 2018;62(5):506–13.PubMedPubMedCentralCrossRef
48.
Edmonston D, Grabner A, Wolf M. FGF23 and klotho at the intersection of kidney and cardiovascular disease. Nat Rev Cardiol, 2023.
49.
Chen W, et al. Predictive value of Noninvasive Peripheral atherosclerosis measurement for coronary artery disease in patients with long T2DM duration. Diabetes Metab Syndr Obes. 2023;16:1075–83.PubMedPubMedCentralCrossRef
50.
Yamada S, Giachelli CM. Vascular calcification in CKD-MBD: roles for phosphate, FGF23, and Klotho. Bone. 2017;100:87–93.PubMedCrossRef
51.
Armutcu F, et al. Oxidative stress markers, C-reactive protein and heat shock protein 70 levels in subjects with metabolic syndrome. Clin Chem Lab Med. 2008;46(6):785–90.PubMedCrossRef
52.
Saito Y, et al. Klotho protein protects against endothelial dysfunction. Biochem Biophys Res Commun. 1998;248(2):324–9.PubMedCrossRef
53.
Yamamoto M, et al. Regulation of oxidative stress by the anti-aging hormone klotho. J Biol Chem. 2005;280(45):38029–34.PubMedCrossRef
54.
Jia Z, et al. Klotho/FGF23 Axis regulates Cardiomyocyte apoptosis and cytokine release through ERK/MAPK pathway. Cardiovasc Toxicol. 2023;23(9–10):317–28.PubMedCrossRef
55.
Zhang W, et al. Secreted klotho protein attenuates osteogenic differentiation of human bone marrow mesenchymal stem cells in vitro via inactivation of the FGFR1/ERK signaling pathway. Growth Factors. 2015;33(5–6):356–65.PubMedCrossRef
Metadata
Title
Relationships of serum FGF23 and α-klotho with atherosclerosis in patients with type 2 diabetes mellitus
Authors
Jiao Bi
Mei Zheng
Ke Li
Siwei Sun
Zihang Zhang
Nana Yan
Xueping Li
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2024
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-024-02205-2

Other articles of this Issue 1/2024

Cardiovascular Diabetology 1/2024 Go to the issue

Research

Association between diabetes mellitus and primary restenosis following endovascular treatment: a comprehensive meta-analysis of randomized controlled trials

Research

Effects of the stress hyperglycemia ratio on long-term mortality in patients with triple-vessel disease and acute coronary syndrome

Research

SGLT1 and SGLT2 inhibition, circulating metabolites, and cerebral small vessel disease: a mediation Mendelian Randomization study

Research

The prognostic impact of insulin resistance surrogates in patients with acute myocardial infarction with and without type 2 diabetes

Research

Heparanase inhibition as a systemic approach to protect the endothelial glycocalyx and prevent microvascular complications in diabetes

Research

Sirolimus-coated balloon in all-comer population of coronary artery disease patients: the EASTBOURNE DIABETES prospective registry
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits